Lung cancer: a business and healthcare imperative

This month, the white ribbon calls us to focus on education, advocacy and leveraging breakthroughs in early detection.

Lung cancer is not a monolith. Medical experts classify it into two primary types based on cellular characteristics and treatment considerations:

Fast-growing and highly aggressive, SCLC accounts for about 15% of cases and is strongly associated with a history of smoking.²

Representing 85% of cases, NSCLC advances more slowly and is further split into subtypes:

Historically, smoking and environmental exposures dominated lung cancer risk models. But that paradigm is shifting. Increasingly, clinicians are diagnosing lung cancer in patients with no known risk factors — non-smokers, younger individuals and those without occupational or environmental exposure histories.⁴

This underscores the critical importance of awareness, vigilance and equitable access to early detection technologies. Lung cancer is no longer confined to “high-risk” groups. It’s a public health imperative that requires proactive screening, research and education across all demographics.

In recent years, lung cancer management has been transformed by discoveries in genomics and precision oncology. Over half of all NSCLC cases exhibit identifiable genetic mutations – such as KRAS, EGFR, ALK, MET, RET, BRAF and ROS1 – that can be targeted with highly effective therapies. For business leaders in healthcare, investing in diagnostic infrastructure and advocating for routine molecular testing at diagnosis are critical steps toward personalized, more effective patient care.

The shift from generalized to personalized therapy underscores the need for health systems and providers to integrate comprehensive molecular diagnostics into lung cancer pathways as a standard of care.⁵

Early detection is the linchpin for improving lung cancer outcomes. The advent of low-dose CT (LDCT) scanning has proven transformative. The U.S. Preventive Services Task Force recommends annual LDCT screening for adults aged 50–80 with a smoking history, resulting in marked increases in early-stage diagnoses and survival rates.⁶

Australia in 2025 and Germany in 2024 launched national LDCT screening programs, joining the U.S. and several Asian countries – including South Korea, Japan and China – in expanding access to life-saving early detection. ^{7 8 9} For executives in healthcare and policy, supporting broad implementation of LDCT screening is both a clinical imperative and a sound investment in population health.

Philips stands at the forefront of lung cancer screening innovation. Philips has specific solutions which harness AI-enabled CT image analysis and aim to streamline diagnostic workflows to support clinicians in identifying lung disease at its earliest, most treatable stages. By combining imaging intelligence, informatics and actionable insights, Philips partners with healthcare systems worldwide to implement scalable, evidence-based lung cancer screening programs.

These initiatives not only enhance the accuracy of diagnosis but help standardize and optimize care on a global scale. For organizations seeking to improve outcomes and reduce the burden of late-stage cancer, technology-driven early detection is essential.

Lung Cancer Awareness Month challenges businesses, healthcare systems and communities to remove stigma, advocate for equitable access to screening and diagnostics, and invest in research that unlocks progress against this deadly disease. Strategic collaborations between technology innovators, clinicians, policymakers and patient advocates are vital for closing gaps in care and delivering on the promise of precision medicine.

Now is the time for decisive leadership – by prioritizing early detection, supporting groundbreaking technologies and fostering a culture of awareness, organizations can help shape a future where early, data-driven lung cancer care is accessible for all.